J.P. Morgan analyst Anupam Rama has maintained their bullish stance on SRPT stock, giving a Buy rating on January 8.
Anupam Rama has given his Buy rating due to a combination of factors highlighting the promising outlook for Sarepta Therapeutics. The strong performance of the Elevidys launch, which has exceeded expectations in terms of revenue, plays a significant role in this positive assessment. Furthermore, the reiterated guidance for 2025 total revenues at $3 billion, primarily driven by Elevidys, underscores the company’s growth potential.
Additional promising developments include the expected top-line data from the EMBARK trial and the anticipated filing of a Biologics License Application for SRP-9003 in 2025. The ongoing expansion of Sarepta’s pipeline, with trials such as SRP-9005, also indicates robust future prospects. These elements combined suggest that Sarepta Therapeutics is well-positioned for long-term success, justifying the Buy rating.
Rama covers the Healthcare sector, focusing on stocks such as Neurocrine, Apellis Pharmaceuticals, and Amicus. According to TipRanks, Rama has an average return of -0.4% and a 42.31% success rate on recommended stocks.
In another report released on January 8, Mizuho Securities also maintained a Buy rating on the stock with a $195.00 price target.
Sarepta Therapeutics (SRPT) Company Description:
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
